LogicBio Therapeutics Inc (NASDAQ:LOGC) saw a significant increase in short interest during the month of August. As of August 31st, there was short interest totalling 130,100 shares, an increase of 12.6% from the July 31st total of 115,500 shares. Approximately 1.0% of the company’s stock are short sold. Based on an average daily trading volume, of 18,500 shares, the days-to-cover ratio is presently 7.0 days.
LogicBio Therapeutics stock traded up $0.44 during midday trading on Friday, reaching $11.78. The company’s stock had a trading volume of 791 shares, compared to its average volume of 27,410. The stock’s 50-day simple moving average is $10.23 and its 200-day simple moving average is $11.84. LogicBio Therapeutics has a 52-week low of $6.34 and a 52-week high of $20.07. The stock has a market capitalization of $250.81 million and a P/E ratio of -3.97.
LogicBio Therapeutics (NASDAQ:LOGC) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.04). Equities research analysts predict that LogicBio Therapeutics will post -1.73 earnings per share for the current year.
A number of equities research analysts have commented on LOGC shares. Chardan Capital reiterated a “buy” rating and issued a $20.00 price target on shares of LogicBio Therapeutics in a research note on Thursday, August 15th. ValuEngine upgraded LogicBio Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Finally, Zacks Investment Research upgraded LogicBio Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, August 23rd. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $24.00.
LogicBio Therapeutics Company Profile
LogicBio Therapeutics, Inc, a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect.
Featured Story: Why do companies pay special dividends?
Receive News & Ratings for LogicBio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LogicBio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.